T0	Participants 40 67	human platelet aggregation.
T1	Participants 443 515	40 aspirin-na√Øve volunteers with at least one cardiovascular risk factor
T2	Participants 608 711	from 20 patients with a prior diagnosis of coronary heart disease who were chronically assuming aspirin